Loading
A phase 3 trial of Acalabrutinib, Bendamustine and Rituximab in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL is a phase 3 interventional study registered as NCT02972840 by Acerta Pharma BV, with 635 participants enrolled, started 2017-04-05 and due to reach its primary completion in 2027-02-15. Interventions recorded: Acalabrutinib, Bendamustine, Rituximab and Placebo.
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised.
Twenty-eight extra months of progression-free survival, with no survival gain and a high rate of severe adverse events in both arms. It set up the two trials that followed: ECHO, which substituted a more selective inhibitor, and ENRICH, which removed the chemotherapy.
Shares Acalabrutinib, Bendamustine, Rituximab, AstraZeneca and the tag pipeline.
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies and the tag pipeline.
Shares Bendamustine, Rituximab, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Bendamustine, Rituximab, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.